Cevimeline

Cevimeline

Cevimeline
Systematic (IUPAC) name
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
Clinical data
Trade names Evoxac
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • C
Legal status
  • (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Protein binding < 20%
Identifiers
CAS Registry Number  Y
ATC code N07
PubChem CID:
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  N
ChEMBL  N
Chemical data
Formula C10H17NOS
Molecular mass 199.31308 g/mol
 N   

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

Contents

  • Mechanism of action 1
  • Side effects 2
  • See also 3
  • References 4
  • External links 5

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.

See also

  • Pilocarpine - a similar parasympathomimetic medication for dry mouth (Xerostomia)
  • Bethanechol - a similar muscarinic parasympathomimetic with longer lasting effect

References

  1. ^ Ono M, Takamura E, Shinozaki K; et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17.  
  2. ^ [2] MedicineNet: Cevimeline. Accessed 10/12/2007

External links

  • Evoxac website